Cassava Sciences to Present at SVB Leerink Global Healthcare Conference
February 23 2021 - 08:30AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company developing product candidates for Alzheimer’s
disease, has been invited to present at the 10th Annual SVB Leerink
Global Healthcare Conference.
Remi Barbier, President & CEO, and Eric
Schoen, Chief Financial Officer, are scheduled to present on
Thursday, February 25th at 2:20pm Eastern time and will participate
in virtual one-on-one meetings with institutional analysts and
investors throughout the conference.
The live webcast of Cassava Sciences’
presentation can be accessed under the ‘Investors’ tab at
www.CassavaSciences.com and will be available for replay through
May 26, 2021.
About Alzheimer's Disease
Alzheimer’s disease is a progressive brain disorder that destroys
memory and thinking skills. Currently, there are no drug therapies
to halt Alzheimer’s disease, much less reverse its course. As of
2020, there were approximately 50 million people worldwide living
with dementia, a figure expected to increase to 150 million by
2050.1 The annual global cost of dementia is now above $1 trillion,
according to Alzheimer’s Disease International, a charitable
organization.
About Simufilam, the Company’s Lead Drug
CandidateSimufilam is a proprietary, small molecule (oral)
drug that restores the normal shape and function of altered filamin
A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the
brain disrupts the normal function of neurons, leading to
Alzheimer’s pathology, neurodegeneration and neuroinflammation. The
underlying science for simufilam is published in peer-reviewed
journals, including Journal of Neuroscience, Neurobiology of Aging,
Journal of Biological Chemistry, Neuroimmunology and
Neuroinflammation and Journal of Prevention of Alzheimer’s Disease.
Cassava Sciences is also developing an investigational diagnostic,
called SavaDx, to detect Alzheimer’s disease with a simple blood
test. Simufilam and SavaDx were both developed in-house. Both
product candidates are substantially funded by peer-review research
grant awards from the National Institutes of Health (NIH). Cassava
Sciences owns worldwide development and commercial rights to its
research programs in Alzheimer’s disease, and related technologies,
without royalty obligations to any third party.
About Cassava Sciences,
Inc.Cassava Sciences’ mission is to discover and develop
innovations for chronic, neurodegenerative conditions. Over the
past 10 years, Cassava Sciences has combined state-of-the-art
technology with new insights in neurobiology to develop novel
solutions for Alzheimer’s disease. For more information, please
visit: https://www.CassavaSciences.com
For More Information
Contact:Eric Schoen, Chief Financial
Officereschoen@CassavaSciences.com(512) 501-2450
_______________1 Alzheimer's Disease International, Dementia
Statistics, available on-line and accessed February 20,
2021:https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2023 to Mar 2024